1 / 94

Enhancing Cancer Care Quality through Identifying and Remedying Care Factors

This study identifies remediable care factors for cancer patients receiving chemotherapy, monoclonal antibodies, or immunotherapy. Experts assessed care aspects and made recommendations for improvement in clinical and organizational practices. The study highlights areas for improvement, such as decision-making, end-of-life care, communication, and safety measures. Recommendations include ensuring time for clinical audits and improving hospital facilities for acutely unwell patients. The study emphasizes the importance of multi-disciplinary team meetings and obtaining informed consent for treatment. Results showed the need for more robust processes in prescribing, administering, and monitoring cancer treatments.

malave
Download Presentation

Enhancing Cancer Care Quality through Identifying and Remedying Care Factors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Aim Identify remediable factors in the care received by patients Proposed by the JSC and JCCO as there was a belief that the standard of care was not uniform across the country

  2. Expert group Medical/clinical and haemato-oncologists Palliative medicine physician Pharmacist Chemotherapy nurse Patient representative

  3. Key areas defined The decision to treat Prescription and administration The safety of treatment End of life care Communication Clinical governance

  4. Inclusion criteria Patients aged 16 years or over Solid tumours or haematological malignancies Received chemotherapy, monoclonal antibodies or immunotherapy during the study period Died within 30 days of receiving treatment

  5. Data collection Questionnaire A Questionnaire B Casenotes Organisational questionnaire

  6. Advisor groups All cases anonymised Clinical/medical/haemato-oncologists Palliative medicine physicians Pharmacists Chemotherapy nurse specialists Assessed all aspects of care

  7. Overall assessment of care Good practice Room for improvement: clinical care Room for improvement: organisational care Room for improvement:clinical care & organisational care Less than satisfactory

  8. Cases identified 47,050 treatment cases 55,710 deaths from any cause 1415 cases identified

  9. Data returned

  10. Recommendation Cancer services managers and clinical directors must ensure that time is made available in consultants’ job plans for clinical audit. They must also ensure that the time allocated is used for the defined purpose. (Cancer Services Managers and Clinical Directors)

  11. Classification of hospitals

  12. Hospital workload

  13. Staffing

  14. Emergency admissions facilities

  15. General medical support

  16. Other specialties onsite Critical care 204/291 Level 3 243/290 Level 2 Palliative care 81/156 consultant palliative care sessions Resuscitation teams 11 hospitals did not have one onsite

  17. Recommendation Hospitals that treat patients with SACT but do not have the facilities to manage patients who are acutely unwell should have a formal agreement with another hospital for the admission or transfer of such patients as appropriate. (Medical directors)

  18. Aim • Interpretation • Limitations • Results

  19. Overall quality of care

  20. Room for improvement • Decision to treat • Process of care • Prescribing, dispensing and administration of SACT • Communication • Patient information, medical records • SACT toxicity • Admission, assessment and treatment • Management of neutropenic sepsis • End of life decisions

  21. Advisors opinion on the decision to treat

  22. Decision to treat

  23. Multi-disciplinary team meetings STANDARD The management of all cancer patients should be discussed at regular MDT meetings. Manual for Cancer Services: 2004

  24. Tumour and patient characteristics • Tumour type • Tumour stage • Previous SACT • Medical complications of malignancy • Patient’s age • Patient’s performance status • Patient’s co-morbidities

  25. Solid tumours

  26. Haematological malignancies

  27. SACT regimens • Carboplatin and Etoposide • Capecitabine • Gemcitabine and Carboplatin • Oxaliplatin • Carboplatin • R-CHOP and CHOP

  28. Performance score

  29. Clinical management plan

  30. Decision to treat

  31. Patient information 433/546 cases

  32. Consent forms 310/546 cases STANDARD Written information should be provided on • treatment intention and expected response rates • acute and possible late side effects • mortality rates Obtaining Consent for Chemotherapy: British Committee for Standards in Haematology Guidelines

  33. Recommendations NCEPOD supports the Manual for Cancer Services standard that initial clinical management plans for all cancer patients should be formulated within a MDT meeting. (Clinical directors)

  34. Recommendations Giving palliative SACT to poor performance status patients grade 3 or 4 should be done so with caution and having been discussed at a MDT meeting. (Consultants)

  35. Recommendations Consent must only be taken by a clinician sufficiently experienced to judge that the patient’s decision has been made after careful consideration of the potential risks and benefits of the treatment, and that treatment is in the patient’s best interest. (Clinical directors)

  36. Recommendations All deaths within 30 days of SACT should be considered at a morbidity and mortality or a clinical governance meeting. (Clinical directors and consultants)

  37. Process of care

  38. Authorisation to prescribe SACT STANDARD Chemotherapy must be initiated and prescribed only by clinicians who are appropriately accredited and/or experienced Good Practice Guidance for Clinical Oncologists: RCR

  39. SACT initiators

  40. SACT prescribers

  41. SACT prescribing accreditation • Independent prescribers n=32 • 6 at the consultant’s discretion • 23 post formal assessment and accreditation • 3 unknown

  42. Initiator, prescriber, reviewer

  43. Pre-treatment investigations

  44. Pre-treatment assessments STANDARDS Toxicity should be recorded for each cycle using the Common Toxicity Criteria The outcomes of treatment should be monitored closely Appropriate action should be taken if - the side-effects are excessive - the cancer progresses. Chemotherapy Guidelines: COIN 2001

  45. Documentation of toxicity and tumour response • Toxicity • Record of assessment – 64% • Toxicity checklist – 26/267 • Tumour response • Record of assessment – 54%

  46. Prescriptions STANDARD All prescriptions of cytotoxic chemotherapy should be computer generated at least when using regimens from the agreed list. Manual for Cancer Services: 2004 n=426

  47. Route of SACT administration

  48. Recommendation All independent and supplementary prescribers (specialist chemotherapy nurses and cancer pharmacists) and junior medical staff should be locally trained/accredited before being authorised to prescribe SACT. (Cancer services managers and clinical directors)

  49. Recommendation Junior medical staff at FY1, FY2, ST1 and ST2 grade should not be authorised to initiate SACT. (Clinical directors) Toxicity check lists should be developed to assist record keeping and aid the process of care in prescribing SACT. (Cancer services managers and clinical directors)

More Related